Aim: Identify biomarker that predicts risk of liver fibrosis (LF). Analyse role of FiB4 score in detecting LF.

Methods: Between Oct’ 22 & Mar’ 23, 66 T2DM patients (waist cmf > 80 cms (F) > 90 cms (M) receiving dapagliflozin irrespective of A1c & who underwent liver fibroscan (Lfib) were retrospectively analysed & studied. LF was performed by Lfib using ARFI. Metavir LF staging classified pt’s: F0 (N); F1 (N - mild); F2 (Mild - mod); F3 (mod - severe); F4 (cirrhosis). Wt-Kg, systolic/diastolic BP (mmHg), Lipid profile mg/dl (TC, LDL-C, TG, HDL), Hs-crp mg/L, LFT, NT-ProBNP pg/ml, eGFR (Cyst-C) & UACR mg/gm were recorded 2-3 mthly & data presented over 1 yr. Exclusion: Preg, <3 mths illness/hospitalisation, alcoholism, hep B, C & autoimmune hepatitis (if LFT was raised). Statistics: ANOVA - compared parameters within stages of LF. One-Way ANOVA, followed by post-hoc Tukey test compared mean TG levels within LF stages. Pearson Chi-square test (comparison of two non-parametric variables) & Spearman rho’s (correlation between Fib4 & LF stages) was used with P-value <0.05 considered statistically significant (S).

Results: Baseline (B) characters: Males 86.4%, avg (age 56.88<u>+</u>8.82, Wt 83.72<u>+</u>11.96, A1c 7.77<u>+</u>1.54, TG 164.16<u>+</u>90.82, hs-CRP 2.57<u>+</u>2.83, GGT 49<u>+</u>51.96 SGPT 40.44<u>+</u>25.89, NT-ProBNP 46.65<u>+</u>45.71, UACR 33.43<u>+</u>99.55 & eGFRCys-C 84.98<u>+</u>20.55. (B) - 1 yr: S reduction in Wt, DBP, A1c, TC, LDL, TG, hs-CRP, SGPT. (B) TG was S different between stages of LF {140.88<u>+</u>71.98 (F0), 143.92<u>+</u>54.32 (F1), 344.33<u>+</u>76.22(F2), 178<u>+</u>51.34 (F3), 259.83<u>+</u>153.64 (F4) p-0.001}. TG >128 (p-0.041) was found S for detecting LF (F2-F4, sensitivity 73.53% & specificity 53.13%). SGPT & GGT (>50) was associated with LF severity (F2-F4), likelihood ratio -4.477 (p-0.031). No correlation was found between FiB4 & stages of LF.

Conclusion: Serum TG is a better predictor compared to FiB4 score in detecting LF in Indian patients with T2DM.

Disclosure

V. Gupta: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.